Jefferies Starts Sangamo BioSciences (SGMO) at Buy

Jefferies initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Buy rating and a price target of $22.00.

Analyst Ryan Martins comments, "We believe SGMO represents the most diversified gene therapy play for investors as its zinc finger protein (ZFP) based therapeutics platform offers multiple strategies and ways to win. HIV clinical data validate the platform and set the stage for the programs in monogenic diseases that have validating partnerships with Shire and Biogen. SGMOs ability to execute on these pipeline programs will be key to long term success."

For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.

Shares of Sangamo BioSciences closed at $10.77 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
• KKR Real Estate Financial Trust (KREF) PT Lowered to $12 at JMP Securities